• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

探索性子组分析中的多重性问题。

Multiplicity issues in exploratory subgroup analysis.

作者信息

Lipkovich Ilya, Dmitrienko Alex, Muysers Christoph, Ratitch Bohdana

机构信息

a QuintilesIMS, Advisory Analytics , Durham , NC , USA.

b Mediana Inc , Overland Park , KS , USA.

出版信息

J Biopharm Stat. 2018;28(1):63-81. doi: 10.1080/10543406.2017.1397009. Epub 2017 Nov 27.

DOI:10.1080/10543406.2017.1397009
PMID:29173045
Abstract

The general topic of subgroup identification has attracted much attention in the clinical trial literature due to its important role in the development of tailored therapies and personalized medicine. Subgroup search methods are commonly used in late-phase clinical trials to identify subsets of the trial population with certain desirable characteristics. Post-hoc or exploratory subgroup exploration has been criticized for being extremely unreliable. Principled approaches to exploratory subgroup analysis based on recent advances in machine learning and data mining have been developed to address this criticism. These approaches emphasize fundamental statistical principles, including the importance of performing multiplicity adjustments to account for selection bias inherent in subgroup search. This article provides a detailed review of multiplicity issues arising in exploratory subgroup analysis. Multiplicity corrections in the context of principled subgroup search will be illustrated using the family of SIDES (subgroup identification based on differential effect search) methods. A case study based on a Phase III oncology trial will be presented to discuss the details of subgroup search algorithms with resampling-based multiplicity adjustment procedures.

摘要

由于亚组识别在定制疗法和个性化医疗的发展中具有重要作用,其总体主题在临床试验文献中备受关注。亚组搜索方法常用于后期临床试验,以识别具有某些理想特征的试验人群子集。事后或探索性亚组探索因极其不可靠而受到批评。基于机器学习和数据挖掘的最新进展,已开发出探索性亚组分析的原则性方法来应对这一批评。这些方法强调基本统计原则,包括进行多重性调整以考虑亚组搜索中固有的选择偏倚的重要性。本文详细回顾了探索性亚组分析中出现的多重性问题。将使用SIDES(基于差异效应搜索的亚组识别)方法族来说明原则性亚组搜索背景下的多重性校正。将呈现一个基于III期肿瘤学试验的案例研究,以讨论基于重采样的多重性调整程序的亚组搜索算法的细节。

相似文献

1
Multiplicity issues in exploratory subgroup analysis.探索性子组分析中的多重性问题。
J Biopharm Stat. 2018;28(1):63-81. doi: 10.1080/10543406.2017.1397009. Epub 2017 Nov 27.
2
Tutorial in biostatistics: data-driven subgroup identification and analysis in clinical trials.生物统计学教程:临床试验中数据驱动的亚组识别与分析
Stat Med. 2017 Jan 15;36(1):136-196. doi: 10.1002/sim.7064. Epub 2016 Aug 3.
3
Multiplicity considerations in subgroup analysis.亚组分析中的多重性考量
Stat Med. 2017 Dec 10;36(28):4446-4454. doi: 10.1002/sim.7416. Epub 2017 Aug 1.
4
Penalty-based approaches to evaluating multiplicity adjustments in clinical trials: Advanced multiplicity problems.基于惩罚的临床试验多重性调整评估方法:高级多重性问题。
J Biopharm Stat. 2018;28(1):169-188. doi: 10.1080/10543406.2017.1397011. Epub 2017 Nov 10.
5
Estimation of treatment effect in two-stage confirmatory oncology trials of personalized medicines.个性化药物两阶段确证性肿瘤学试验中治疗效果的评估。
Stat Med. 2017 May 30;36(12):1843-1861. doi: 10.1002/sim.7272. Epub 2017 Mar 17.
6
Addressing multiplicity issues of a composite endpoint and its components in clinical trials.解决临床试验中复合终点及其组成部分的多重性问题。
J Biopharm Stat. 2011 Jul;21(4):610-34. doi: 10.1080/10543406.2011.551327.
7
An enhanced mixture method for constructing gatekeeping procedures in clinical trials.一种用于构建临床试验中守门程序的改进混合方法。
J Biopharm Stat. 2018;28(1):113-128. doi: 10.1080/10543406.2017.1399900. Epub 2017 Dec 14.
8
Key multiplicity issues in clinical drug development.临床药物研发中的关键多重性问题。
Stat Med. 2013 Mar 30;32(7):1079-111. doi: 10.1002/sim.5642. Epub 2012 Oct 9.
9
Data-Driven Subgroup Identification in Confirmatory Clinical Trials.确证性临床试验中基于数据的亚组识别
Ther Innov Regul Sci. 2022 Jan;56(1):65-75. doi: 10.1007/s43441-021-00329-1. Epub 2021 Jul 29.
10
Biomarker threshold adaptive designs for survival endpoints.用于生存终点的生物标志物阈值适应性设计。
J Biopharm Stat. 2018;28(6):1038-1054. doi: 10.1080/10543406.2018.1434191. Epub 2018 Feb 13.

引用本文的文献

1
Differential Treatment Effects of Subgroup Analyses in Phase 3 Oncology Trials From 2004 to 2020.2004 年至 2020 年,3 期肿瘤试验亚组分析的差异化治疗效果。
JAMA Netw Open. 2024 Mar 4;7(3):e243379. doi: 10.1001/jamanetworkopen.2024.3379.
2
A novel concept of screening for subgrouping factors for the association between socioeconomic status and respiratory allergies.一种用于筛选社会经济地位与呼吸道过敏关联的亚组因素的新方法。
J Expo Sci Environ Epidemiol. 2022 Mar;32(2):295-302. doi: 10.1038/s41370-021-00365-x. Epub 2021 Jul 12.
3
Q-Finder: An Algorithm for Credible Subgroup Discovery in Clinical Data Analysis - An Application to the International Diabetes Management Practice Study.
Q-Finder:一种用于临床数据分析中可信亚组发现的算法——在国际糖尿病管理实践研究中的应用
Front Artif Intell. 2020 Dec 17;3:559927. doi: 10.3389/frai.2020.559927. eCollection 2020.
4
Development of the Instrument to assess the Credibility of Effect Modification Analyses (ICEMAN) in randomized controlled trials and meta-analyses.随机对照试验和荟萃分析中效应修饰分析可信度评估工具(ICEMAN)的开发。
CMAJ. 2020 Aug 10;192(32):E901-E906. doi: 10.1503/cmaj.200077.
5
Reporting of health equity considerations in cluster and individually randomized trials.报告群组随机和个体随机试验中的健康公平性考虑因素。
Trials. 2020 Apr 3;21(1):308. doi: 10.1186/s13063-020-4223-5.
6
A critical review of graphics for subgroup analyses in clinical trials.对临床试验亚组分析图表的批判性综述。
Pharm Stat. 2020 Sep;19(5):541-560. doi: 10.1002/pst.2012. Epub 2020 Mar 25.
7
Early onset of efficacy with erenumab in patients with episodic and chronic migraine.依瑞奈尤单抗治疗发作性和慢性偏头痛患者的早期疗效。
J Headache Pain. 2018 Oct 1;19(1):92. doi: 10.1186/s10194-018-0923-6.